Comparative_JJ Activities_NNS of_IN the_DT Oxazolidinone_NP AZD2563_NP and_CC Linezolid_NP against_IN Selected_NP Recent_JJ North_NP American_NP Isolates_NP of_IN Streptococcus_NP pneumoniae_NNS The_DT activity_NN of_IN AZD2563_NP against_IN 250_CD highly_RB resistant_JJ pneumococci_NNS and_CC 267_CD drug-susceptible_JJ isolates_NNS was_VBD determined_VBN ._SENT The_DT AZD2563_NP MICs_NP for_IN 50_CD and_CC 90_CD %_NN of_IN the_DT strains_NNS tested_VBN were_VBD 1_CD and_CC 2_CD mug/ml_NN and_CC 0.5_CD and_CC 1_CD mug/ml_NN ,_, respectively_RB ,_, for_IN the_DT two_CD isolate_NN groups_NNS ._SENT These_DT MICs_NP were_VBD within_IN 1_CD log2_JJ dilution_NN of_IN those_DT of_IN linezolid_NN ._SENT The_DT incidence_NN of_IN penicillin_NN resistance_NN and_CC multidrug_NN resistance_NN in_IN Streptococcus_NP pneumoniae_NNS has_VBZ continued_VBN to_TO increase_NN and_CC has_VBZ altered_VBN empirical_JJ choices_NNS of_IN therapy_NN for_IN invasive_JJ pneumococcal_JJ infections_NNS ._SENT Multidrug_NN resistance_NN to_TO three_CD or_CC more_JJR drug_NN classes_NNS has_VBZ made_VBN therapy_NN for_IN serious_JJ infections_NNS challenging_VBG ,_, especially_RB in_IN severely_RB ill_JJ patients_NNS ._SENT Resistance_NN to_TO traditional_JJ choices_NNS for_IN therapy_NN of_IN pneumococcal_JJ infections_NNS (_( e.g._FW ,_, beta-lactams_NNS ,_, macrolides_NN )_) has_VBZ prompted_VBN investigation_NN of_IN the_DT activities_NNS of_IN newer_JJR agents_NNS (_( e.g._FW ,_, fluoroquinolones_NNS ,_, ketolides_NNS ,_, carbapenems_NNS ,_, and_CC oxazolidinones_NNS )_) for_IN predictable_JJ activity_NN against_IN highly_RB resistant_JJ strains_NNS ._SENT Linezolid_NP was_VBD approved_VBN by_IN the_DT U.S._NP Food_NP and_CC Drug_NP Administration_NP in_IN 2000_CD and_CC represents_VBZ the_DT first_JJ oxazolidinone_NN compound_NN to_TO reach_VB clinical_JJ use_NN ._SENT It_PP is_VBZ indicated_VBN for_IN therapy_NN of_IN serious_JJ infections_NNS due_JJ to_TO resistant_JJ staphylococci_NNS or_CC enterococci_NNS and_CC also_RB for_IN community-acquired_JJ pneumonia_NN due_JJ to_TO S._NP pneumoniae_NNS ._SENT Oxazolidinones_NP bind_NN to_TO the_DT 50S_JJ ribosomal_JJ subunit_NN and_CC inhibit_VB protein_NN synthesis_NN by_IN a_DT unique_JJ mechanism_NN that_WDT does_VBZ not_RB appear_VB to_TO share_VB cross-resistance_NN with_IN other_JJ protein_NN synthesis_NN inhibitors_NNS ._SENT Although_IN resistance_NN to_TO linezolid_NN has_VBZ been_VBN found_VBN in_IN Enterococcus_NP isolates_NNS (_( G._NP E._NP Zurenko_NP ,_, W._NP M._NP Todd_NP ,_, B._NP Hafkin_NP ,_, B._NP Meyers_NP ,_, C._NP Kauffman_NP ,_, J._NP Bock_NP ,_, J._NP Slighton_NP ,_, and_CC D._NP Shinabarger_NP ,_, Abstr_NP ._SENT 39th_JJ Intersci_NP ._SENT Conf_NP ._SENT Antimicrob_NN ._SENT Agents_NPS Chemother_NP ._SENT ,_, abstr_NN ._SENT 848_CD ,_, 1999_CD )_) and_CC more_RBR recently_RB in_IN Staphylococcus_NP aureus_NN ,_, it_PP has_VBZ not_RB been_VBN found_VBN in_IN S._NP pneumoniae_NNS or_CC other_JJ streptococci_NNS ._SENT AZD2563_NP is_VBZ a_DT newer_JJR member_NN of_IN the_DT oxazolidinone_NN class_NN that_WDT is_VBZ currently_RB under_IN development_NN ._SENT Two_CD hundred_CD fifty_CD isolates_NNS of_IN S._NP pneumoniae_NNS with_IN previously_RB determined_VBN resistance_NN to_TO one_CD or_CC more_JJR of_IN the_DT antimicrobial_JJ agents_NNS currently_RB in_IN use_NN were_VBD tested_VBN against_IN AZD2563_NP and_CC selected_VBN comparative_JJ agents_NNS ._SENT A_DT group_NN of_IN 267_CD drug-susceptible_NN ,_, invasive_JJ pneumococcal_JJ isolates_NNS were_VBD chosen_VBN from_IN among_IN the_DT 1998_CD to_TO 2000_CD Centers_NPS for_IN Disease_NP Control_NP and_CC Prevention_NP Active_NP Bacterial_NP Core_NP Surveillance/Emerging_NP Infections_NNS Program_NN collection_NN ._SENT MICs_NNS of_IN AZD2563_NP ,_, linezolid_NN ,_, quinupristin-dalfopristin_NP ,_, erythromycin_NN ,_, clindamycin_NN ,_, penicillin_NN ,_, levofloxacin_NN ,_, and_CC vancomycin_NP were_VBD determined_VBN by_IN the_DT broth_NN microdilution_NN method_NN recommended_VBN by_IN the_DT NCCLS_NP ._SENT This_DT included_VBD cation-adjusted_JJ Mueller-Hinton_NP broth_NN supplemented_VBD with_IN 3_CD %_NN lysed_VBD horse_NN blood_NN prepared_VBN as_IN frozen_JJ microdilution_NN panels_NNS (_( Trek_NP Diagnostic_NP Systems_NPS Inc._NP ,_, Westlake_NP ,_, Ohio_NP )_) ,_, an_DT inoculum_NN of_IN approximately_RB 5_CD x_SYM 105_CD CFU/ml_NN ,_, and_CC incubation_NN at_IN 35C_JJ for_IN 20_CD to_TO 24_CD h_NN in_IN ambient_JJ air_NN prior_RB to_TO visual_JJ MIC_JJ determination_NN ._SENT S._NP pneumoniae_NNS ATCC_NP 49619_CD was_VBD included_VBN with_IN each_DT day_NN 's_POS testing_NN as_IN a_DT control_NN organism_NN ._SENT Susceptibility_NN results_NNS obtained_VBN for_IN the_DT entire_JJ collection_NN of_IN 517_CD S._NP pneumoniae_NNS isolates_NNS with_IN AZD2563_NP and_CC the_DT other_JJ comparator_NN agents_NNS are_VBP depicted_VBN in_IN Table_NP ._SENT Among_IN the_DT drug-susceptible_JJ isolates_NNS ,_, the_DT MICs_NP of_IN AZD2563_NP for_IN 50_CD and_CC 90_CD %_NN of_IN the_DT isolates_NNS tested_VBN (_( MIC50_NP and_CC MIC90_NP ,_, respectively_RB )_) were_VBD 0.5_CD and_CC 1.0_CD mug/ml_NN ,_, respectively_RB ,_, versus_CC 1_CD and_CC 2_CD mug_NN of_IN linezolid_NN per_IN ml_NN ._SENT Among_IN the_DT drug-resistant_JJ isolates_NNS ,_, the_DT MIC50_NP and_CC MIC90_NP were_VBD 1_CD dilution_NN higher_JJR and_CC identical_JJ to_TO those_DT of_IN linezolid_NN for_IN this_DT group_NN ._SENT For_IN both_DT groups_NNS of_IN isolates_NNS ,_, the_DT MIC90_NP for_IN AZD2563_NP was_VBD 2_CD mug/ml_NN ._SENT TABLE_NN 1_CD |_SYM Susceptibilities_NNS of_IN selected_JJ S._NP pneumoniae_NNS clinical_JJ isolates_NNS to_TO AZD2563_NP ,_, linezolid_NN ,_, and_CC representative_JJ agents_NNS of_IN various_JJ other_JJ antimicrobial_JJ classes_NNS Figure_NN shows_VBZ the_DT distributions_NNS of_IN linezolid_NP and_CC AZD2563_NP MICs_NP for_IN the_DT drug-resistant_JJ and_CC drug-susceptible_JJ groups_NNS ,_, respectively_RB ._SENT The_DT geometric_JJ mean_JJ MICs_NN of_IN AZD2563_NP were_VBD 0.70_CD and_CC 0.94_CD mug/ml_NN for_IN the_DT susceptible_JJ and_CC resistant_JJ groups_NNS ,_, respectively_RB ,_, compared_VBN to_TO 0.99_CD and_CC 1.14_CD mug/ml_NN ,_, respectively_RB ,_, for_IN linezolid_NN ._SENT For_IN 218_CD isolates_NNS ,_, the_DT MICs_NP of_IN linezolid_NP and_CC AZD2563_NP were_VBD different_JJ ._SENT For_IN 211_CD (_( 96.8_CD %_NN )_) of_IN these_DT ,_, the_DT AZD2563_NP MIC_NP was_VBD lower_JJR than_IN that_IN of_IN linezolid_NN ._SENT Of_IN these_DT ,_, one_PP was_VBD lower_JJR by_IN 2_CD dilutions_NNS ;_: all_DT others_NNS were_VBD lower_JJR by_IN a_DT single_JJ dilution_NN ._SENT In_IN seven_CD cases_NNS (_( 3.2_CD %_NN )_) ,_, the_DT MIC_NN was_VBD lower_JJR by_IN a_DT single_JJ dilution_NN for_IN linezolid_NN ._SENT MICs_NNS of_IN linezolid_NN were_VBD never_RB lower_JJR than_IN those_DT of_IN AZD2563_NP by_IN more_JJR than_IN a_DT single_JJ dilution_NN ._SENT FIG._NN 1_CD ._SENT |_SYM MICs_NP (_( micrograms_NNS per_IN milliliter_NN )_) of_IN AZD2563_NP (_( AZD_NP )_) and_CC linezolid_NP (_( LZD_NP )_) for_IN 250_CD drug-resistant_JJ S._NP pneumoniae_NNS MICs_NN (_( micrograms_NNS per_IN milliliter_NN )_) of_IN AZD2563_NP (_( AZD_NP )_) and_CC linezolid_NP (_( LZD_NP )_) for_IN 250_CD drug-resistant_JJ S._NP pneumoniae_NNS isolates_VBZ (_( A_NP )_) and_CC 267_CD drug-susceptible_JJ S._NP pneumoniae_NNS isolates_VBZ (_( B_NP )_) ._SENT Because_IN of_IN the_DT rising_VBG rate_NN of_IN resistance_NN in_IN pneumococci_NNS and_CC the_DT potential_NN for_IN development_NN of_IN resistance_NN to_TO antibiotics_NNS that_WDT have_VBP thus_RB far_RB been_VBN universally_RB active_JJ ,_, new_JJ agents_NNS are_VBP needed_VBN to_TO provide_VB predictable_JJ activity_NN against_IN multidrug-resistant_JJ strains_NNS ._SENT Linezolid_NP has_VBZ been_VBN shown_VBN to_TO have_VB almost_RB universal_JJ activity_NN against_IN multiply_RB resistant_JJ isolates_NNS of_IN enterococci_NNS ,_, staphylococci_NNS ,_, and_CC S._NP pneumoniae_NNS ._SENT The_DT newer_JJR oxazolidinone_NN AZD2563_NP has_VBZ been_VBN shown_VBN in_IN this_DT study_NN to_TO have_VB activity_NN very_RB similar_JJ to_TO that_DT of_IN linezolid_NN against_IN highly_RB resistant_JJ ,_, as_RB well_RB as_IN susceptible_JJ ,_, recent_JJ clinical_JJ isolates_NNS of_IN S._NP pneumoniae_NNS from_IN geographically_RB diverse_JJ regions_NNS of_IN the_DT United_NP States_NPS ._SENT While_IN susceptibility_NN breakpoints_NNS have_VBP not_RB been_VBN determined_VBN for_IN AZD2563_NP ,_, the_DT MIC50_NP and_CC MIC90_NP of_IN AZD2563_NP appear_VBP to_TO be_VB similar_JJ to_TO or_CC slightly_RB lower_JJR than_IN those_DT of_IN linezolid_NN ._SENT Pharmacokinetic_JJ data_NNS regarding_VBG levels_NNS of_IN AZD2563_NP in_IN blood_NN ,_, cerebrospinal_JJ fluid_NN ,_, and_CC other_JJ bodily_JJ fluid_NN are_VBP needed_VBN to_TO put_VB into_IN perspective_NN this_DT slightly_RB greater_JJR potency_NN of_IN AZD2563_NP ._SENT The_DT isolates_NNS included_VBD in_IN this_DT study_NN were_VBD representative_JJ of_IN all_DT known_VBN resistance_NN phenotypes_NNS of_IN S._NP pneumoniae_NNS (_( including_VBG beta-lactam_NN ,_, macrolide_NN ,_, lincosamide_NN ,_, fluoroquinolone_NN ,_, and_CC streptogramin_NN resistance_NN )_) ,_, and_CC regardless_RB of_IN the_DT phenotype_NN selected_VBD ,_, all_DT isolates_NNS were_VBD inhibited_VBN by_IN AZD2563_NP at_IN <=2_JJ mug/ml_NN ._SENT Thus_RB ,_, as_RB with_IN linezolid_NN ,_, no_DT cross-resistance_NN to_TO AZD2563_NP and_CC other_JJ classes_NNS of_IN antibiotics_NNS was_VBD observed_VBN ._SENT This_DT may_MD be_VB a_DT result_NN of_IN the_DT unique_JJ mechanism_NN of_IN action_NN of_IN the_DT oxazolidinones_NNS ,_, which_WDT appears_VBZ to_TO be_VB inhibition_NN of_IN translation_NN of_IN rRNA_NN ._SENT Linezolid_NP has_VBZ been_VBN demonstrated_VBN to_TO be_VB effective_JJ in_IN the_DT treatment_NN of_IN several_JJ serious_JJ gram-positive_JJ infections_NNS ,_, including_VBG community-acquired_JJ pneumonia_NN ._SENT Given_VBN the_DT similar_JJ activities_NNS of_IN AZD2563_NP and_CC linezolid_NN against_IN S._NP pneumoniae_NNS ,_, AZD2563_NP could_MD also_RB prove_VB to_TO be_VB useful_JJ for_IN therapy_NN in_IN patients_NNS with_IN severe_JJ infections_NNS caused_VBN by_IN resistant_JJ organisms_NNS ._SENT Additional_JJ studies_NNS are_VBP needed_VBN to_TO determine_VB its_PP$ pharmacokinetics_NNS ,_, safety_NN ,_, and_CC in_IN vivo_JJ clinical_JJ efficacy_NN against_IN invasive_JJ pneumococcal_JJ infections_NNS in_IN humans_NNS ._SENT 